| Literature DB >> 35071609 |
Zaed M Mazayen1, Amira M Ghoneim1, Rasha S Elbatanony1, Emad B Basalious2, Ehab R Bendas1.
Abstract
BACKGROUND: Nanotechnology is considered a new and rapidly emerging area in the pharmaceutical and medicinal field. Nanoparticles, as drug delivery systems, impart several advantages concerning improved efficacy as well as reduced adverse drug reactions. MAIN BODY: Different types of nanosystems have been fabricated including carbon nanotubes, paramagnetic nanoparticles, dendrimers, nanoemulsions, etc. Physicochemical properties of the starting materials and the selected method of preparation play a significant aspect in determining the shape and characteristics of the developed nanoparticles. Dispersion of preformed polymers, coacervation, polymerization, nano-spray drying and supercritical fluid technology are among the most extensively used techniques for the preparation of nanocarriers. Particle size, surface charge, surface hydrophobicity and drug release are the main factors affecting nanoparticles physical stability and biological performance of the incorporated drug. In clinical practice, many nanodrugs have been used for both diagnostic and therapeutic applications and are being investigated for various indications in clinical trials. Nanoparticles are used for the cure of kidney diseases, tuberculosis, skin conditions, Alzheimer's disease, different types of cancer as well as preparation of COVID-19 vaccines.Entities:
Keywords: Applications; Characterization; Delivery systems; Fabrication; Nanotechnology
Year: 2022 PMID: 35071609 PMCID: PMC8760885 DOI: 10.1186/s43094-022-00400-0
Source DB: PubMed Journal: Futur J Pharm Sci ISSN: 2314-7245
Examples of FDA-approved nanomedicines
| Trade name | Material description | Advantages | Indications | Approval year |
|---|---|---|---|---|
| Estrasorb™ | Micellar Estradiol | Controlled delivery of the drug | Menopausal therapy | 2003 |
| Marqibo® | Liposomal Vincristine | Increased delivery to tumor tissue; decreased systemic toxicity resulting from side-effects | Acute lymphoblastic leukemia | 2012 |
| Onivyde® | Liposomal Irinotecan | Pancreatic cancer | 2015 | |
| BNT162b2 vaccine (developed by BioNTech and Pfizer) | Nucleoside modified mRNA encoding the viral spike glycoprotein of SARS-CoV-2, encapsulated in lipid nanoparticles | Protection of the non-replicating RNA from degradation and allow it to be delivered into host cells after intramuscular injection | Prevention of coronavirus disease | 2020 |
| mRNA-1273 vaccine (developed by Moderna) | Lipid nanoparticle-encapsulated mRNA-based vaccine, which encodes the spike protein (S protein) of SARS-CoV-2 | Lipid nanoparticles are playing a key role in protecting and transporting the mRNA effectively to the right place in cells | Prevention of coronavirus disease | 2020 |